Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) agreed to acquire Biosimilar Tocilizumab from Mycenax Biotech Inc. (TPEX:4726) for TWD 19.5 million on April 29, 2020. The Parties have agreed that the price payable by Richter in four installments amounts to TWD 16.5 million.

Richter made a down payment of TWD 2 million for exclusive negotiation rights and will pay upon signature an additional TWD 3 million as upfront payment. The Product is expected to reach the market in the European Union, Canada, Australia and Japan during 2025.